Could a UK manufacturing partner strengthen your US healthcare supply chain?
For US longevity clinics, healthcare suppliers, pharmacy-sector businesses and specialist distributors, finding the right manufacturing partner is about more than securing product. It is about building a dependable supply chain with appropriate environmental controls, quality oversight, traceability and the ability to support future growth.
Thanet Labs is a UK-based peptide manufacturing company focused on specialist aseptic fill-finish, lyophilisation and advanced drug-delivery formats. We are seeking conversations with established US distribution partners, healthcare suppliers and organisations serving clinics that want to explore a long-term relationship with a capable UK manufacturing partner.
Our aim is straightforward: to combine controlled UK manufacturing with experienced, appropriately authorised US partners that understand their market, customers and regulatory responsibilities.
Who should consider working with Thanet Labs?
Thanet Labs is interested in hearing from:
- longevity, wellness and preventative-health clinic networks;
- specialist healthcare and medical-product distributors;
- suppliers serving clinics and pharmacy-sector businesses;
- outsourcing and compounding-sector organisations seeking complementary manufacturing capabilities;
- pharmaceutical brands looking for vial, cartridge or lyophilised formats;
- importers and commercial partners able to manage compliant US market access; and
- businesses seeking a UK supply partner for specialist or technically demanding projects.
We are particularly interested in distribution partners that already have trusted relationships with clinics, healthcare professionals, pharmacies or specialist providers across the United States.
What manufacturing capabilities does Thanet Labs offer?
Thanet Labs is developing a flexible platform for small- and medium-volume specialist pharmaceutical projects. Our capabilities include:
- aseptic liquid filling;
- vial and cartridge fill-finish;
- lyophilisation, also known as freeze-drying;
- single- and dual-chamber cartridge development;
- formulation and process-development support;
- controlled component and raw-material handling;
- batch and lot traceability;
- in-process quality controls; and
- coordination of independent analytical testing where required.
This flexibility may be valuable to US partners that need more attentive technical support than a very large contract manufacturer can provide, particularly during product development, initial commercialisation or the introduction of a new delivery format.
Does Thanet Labs manufacture in an ISO 5 environment?
Yes. Thanet Labs uses ISO 5 controlled conditions for critical aseptic processing activities. ISO 5 describes the airborne particle cleanliness of the environment in which exposed sterile product, components and critical operations are handled.
However, ISO 5 is only one part of a robust pharmaceutical quality system. Environmental classification alone does not make a product compliant, sterile or suitable for use. Appropriate manufacturing also depends on validated processes, trained personnel, contamination-control measures, documented procedures, environmental monitoring, material controls, testing and complete batch records.
Our operating model brings these controls together to support consistent, traceable manufacturing.
What does cGMP mean in this context?
Current Good Manufacturing Practice, commonly called cGMP, is the quality framework used to ensure pharmaceutical products are consistently manufactured and controlled according to their intended specification.
Thanet Labs is building and operating its manufacturing systems around cGMP principles, including:
- documented procedures and controlled records;
- supplier and incoming-material qualification;
- equipment qualification and maintenance;
- personnel training and gowning controls;
- contamination-control and environmental-monitoring programmes;
- deviation, change-control and corrective-action processes;
- batch traceability and reconciliation; and
- product-specific testing and release requirements.
The exact regulatory route, licence requirements and release arrangements depend on the product, its intended use and the market in which it will be supplied. Any statement about cGMP compliance should therefore be assessed against the specific manufacturing activity, product and applicable regulatory authorisation—not environmental classification alone.
Why might US clinics and suppliers source from the UK?
A UK manufacturing relationship can give US commercial partners a valuable second supply route and access to specialist technical capabilities. Potential advantages include:
Supply-chain diversification
Depending on a single country, manufacturer or source can expose a business to shortages, delays and inconsistent quality. A qualified UK partner may help create greater resilience.
Why are US clinics reconsidering peptide supply chains?
Many clinics and suppliers currently depend on peptide material sourced through overseas marketplaces, brokers or trading companies, including supply chains originating in China. China has capable manufacturers, so country of origin alone is not evidence of poor quality. The real concern is whether the clinic or distributor can verify the identity of the original manufacturer, the provenance of the material, the integrity of the batch and the methods behind its Certificate of Analysis.
Common risks in an opaque or heavily brokered supply chain can include:
- incomplete or generic Certificates of Analysis;
- certificates that cannot be matched reliably to the batch received;
- testing limited to an HPLC purity percentage;
- no independent confirmation of peptide identity or actual content;
- limited information about impurities, endotoxins, microorganisms or elemental contaminants;
- inconsistent results between batches;
- unclear storage and transport conditions; and
- multiple intermediaries, each adding cost without necessarily adding quality oversight.
A high HPLC purity result is useful, but it does not by itself prove that the material is the correct peptide, that it was synthesised correctly, or that a vial contains the stated quantity. A chromatogram may show that the principal detected peak represents a high percentage of the detected material. It does not automatically establish molecular identity, potency, sterility or freedom from endotoxin.
This distinction is critical for clinics. “Purity,” “identity” and “assay” are related but separate quality attributes:
- Purity asks: how much of the detected material is the principal component rather than related impurities?
- Identification asks: is the principal component genuinely the peptide stated on the label?
- Assay or content asks: how much of that peptide is actually present?
For example, a sample could report high chromatographic purity while still containing less peptide than expected because the remaining mass consists of water, salts, counterions or other non-peptide material. It could also produce a prominent chromatographic peak without HPLC alone providing sufficiently specific confirmation of molecular identity. That is why a meaningful quality package needs several complementary tests rather than a single purity number.
What testing does Thanet Labs provide, and why does each test matter?
Thanet Labs can provide a broader product-specific analytical and microbiological testing package, with traceability to the relevant batch. The precise specification and release panel must be agreed for each product and intended market, but available testing includes:
| Test | What it establishes | Why it matters to clinics and distributors |
|---|---|---|
| Assay, purity and identification by HPLC | Assay measures the amount of peptide present; purity assesses the proportion of the principal peptide peak relative to detected related substances; comparison with an appropriate reference and validated method contributes to identity confirmation. | Helps establish whether the batch contains the expected amount and meets the agreed purity specification, rather than relying on an unsupported label claim. HPLC should be interpreted with complementary identification data where necessary. |
| LAL bacterial endotoxin testing to Ph. Eur. requirements | Detects and quantifies bacterial endotoxins from Gram-negative bacteria. | A product can pass a sterility test yet still contain endotoxin. Endotoxins may cause serious pyrogenic reactions, so this is a distinct and essential control for parenteral products. |
| Bioburden screening | Measures viable microorganisms present before sterilisation or at a defined stage of manufacture. | Demonstrates how well the manufacturing process controls microbial contamination and helps confirm that the process is not relying on a final sterile test to compensate for poor upstream controls. |
| Impurity profiling by LC-MS | Separates impurities and uses mass information to help characterise the principal peptide and related substances, such as truncated sequences, deletion products or synthesis-related variants. | Provides more specific information than a purity percentage alone and can expose unwanted molecular species that may otherwise sit behind an apparently strong headline purity result. |
| Sterility testing | Tests for viable contaminating microorganisms using the applicable pharmacopeial method. | Provides release evidence concerning microbial sterility. It remains one component of sterility assurance and must be supported by validated aseptic processing, environmental controls and container-closure integrity. |
| Heavy metals by ICP-MS | Measures trace elemental contaminants with high sensitivity. | Helps identify contamination that can arise from raw materials, catalysts, equipment or processing. These contaminants are not revealed by an ordinary HPLC purity result. |
No single test can establish every aspect of peptide quality. Used together, these tests create a substantially more informative picture of identity, content, purity, microbial quality and chemical contamination. Product release must still be based on a defined specification, appropriate validated or qualified methods, representative sampling and review by authorised quality personnel.
How can a more direct supply relationship improve clinic margins?
For suitably authorised US organisations, a more direct relationship with a UK manufacturer may reduce unnecessary broker and reseller layers. This can improve commercial visibility and potentially increase gross margin while giving the buyer clearer access to batch documentation, manufacturing information and technical support.
The value is not simply a lower unit price. A transparent direct-supply model may also reduce hidden costs associated with rejected batches, repeat testing, inconsistent fill quantities, supply interruptions, patient complaints and stock that cannot be confidently released.
Depending on the agreed structure, Thanet Labs can work with an authorised importer or distributor to provide clinics with:
- a clearer manufacturer-to-buyer chain of custody;
- batch- and lot-specific documentation;
- an agreed analytical testing panel;
- consistent product and packaging specifications;
- improved demand forecasting and production planning;
- fewer commercial intermediaries; and
- a scalable route for clinic networks or buying groups.
Any direct commercial arrangement must still follow the applicable US importation, distribution, pharmacy and healthcare requirements. The objective is not to bypass regulated channels, but to create a shorter and more accountable supply chain through appropriately licensed partners.
Specialist manufacturing support
Projects involving aseptic filling, lyophilisation or cartridges require more than general contract packing. They need a manufacturer that understands formulation behaviour, container-closure systems, fill accuracy, stoppering, freeze-drying cycles and finished-product controls.
Traceability and quality documentation
Professional distributors and clinical organisations need confidence in where materials came from, how a batch was processed and what testing supports it. Thanet Labs is building end-to-end batch and lot traceability into its operations.
Flexible commercial development
Emerging brands and specialist distributors may need a partner willing to discuss pilot work, initial production volumes and a pathway to scale rather than demanding mass-market volumes from the outset.
Can Thanet Labs supply products directly to US clinics or compounding pharmacies?
Potential supply must be evaluated product by product. The answer depends on factors including the product’s legal status, intended use, formulation, claims, prescription status, import route and the licences or registrations held by every party in the supply chain.
Thanet Labs does not suggest that UK manufacture alone makes a product lawful for importation, compounding, dispensing or clinical use in the United States. US importers, distributors, pharmacies and healthcare providers must operate within applicable federal and state requirements, including relevant FDA and state pharmacy rules.
For that reason, our preferred approach is to work with experienced US partners that can establish the correct regulatory and commercial route before supply begins.
What kind of US distribution partner is Thanet Labs looking for?
The strongest partner will usually have:
- an established network of clinics, pharmacies, healthcare providers or specialist buyers;
- a clear understanding of federal and state regulatory requirements;
- appropriate licences, registrations and import capabilities for the proposed activity;
- the ability to forecast demand and manage inventory responsibly;
- a commitment to product quality, traceability and transparent marketing; and
- an interest in building a repeatable, long-term supply relationship.
We are open to discussing regional, national and product-specific arrangements. The right structure could include distribution, contract manufacturing, private-label supply, product-development collaboration or a staged market-entry programme, subject to regulatory and quality review.
How would a partnership begin?
A typical initial discussion would cover:
- the organisation, customer base and US states served;
- the proposed product category and intended use;
- expected formats, such as vials or cartridges;
- projected order volumes and launch timetable;
- required testing, documentation and release specifications;
- the proposed importer and distribution route; and
- the regulatory responsibilities of each party.
Following an initial fit assessment, Thanet Labs can review technical feasibility, manufacturing requirements, indicative volumes and the quality documentation needed for the proposed programme.
Frequently asked questions
Is Thanet Labs based in the United States?
No. Thanet Labs is based in the United Kingdom and is exploring relationships with suitably qualified US importers, distributors, suppliers and commercial partners.
Does Thanet Labs work with longevity clinics?
We are interested in supporting legitimate businesses serving longevity, preventative-health and specialist clinical markets where the proposed product and supply route are lawful and appropriately controlled.
Can Thanet Labs manufacture lyophilised products?
Yes. Lyophilisation is a core area of focus, alongside aseptic liquid filling and vial and cartridge fill-finish. Every project requires a technical and regulatory feasibility assessment.
What is the difference between ISO 5 and cGMP?
ISO 5 is an environmental cleanliness classification for airborne particles. cGMP is a much broader quality framework covering people, premises, equipment, materials, processes, documentation, testing and oversight. A credible sterile-manufacturing programme needs both suitable clean conditions and a comprehensive pharmaceutical quality system.
Is Thanet Labs seeking exclusive distributors?
Thanet Labs is open to discussing exclusive or non-exclusive structures where the proposed territory, volumes, capabilities and responsibilities support a sustainable partnership. No exclusivity should be assumed until it is agreed contractually.
Explore a UK–US manufacturing and distribution partnership
If your organisation supplies US clinics, supports pharmacy-sector businesses or distributes specialist healthcare products, Thanet Labs would welcome a confidential introductory conversation.
Tell us:
- who your organisation currently serves;
- which US states or territories you cover;
- the product types and formats you are considering;
- your anticipated volumes and timing; and
- how you currently manage importation, regulatory review and distribution.
Together, we can determine whether Thanet Labs’ UK manufacturing capabilities and your US market reach provide the foundations for a compliant, scalable and commercially valuable partnership.
Contact Thanet Labs to discuss US distribution, contract manufacturing or strategic supply opportunities.
Regulatory note: This article is intended for business-to-business information only. It does not constitute medical or legal advice, an offer to supply any specific medicine, or a representation that any product may lawfully be imported, compounded, prescribed, dispensed or administered in the United States. Product-specific legal, regulatory and quality review is required before manufacture or supply.